Valneva (VALN) Projected to Post Earnings on Thursday

Valneva (NASDAQ:VALN) is expected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Valneva to announce earnings of ($0.1886) per share and revenue of $44.17 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:00 AM ET.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The business had revenue of $35.77 million during the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. On average, analysts expect Valneva to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Valneva Trading Up 5.5%

NASDAQ VALN opened at $5.59 on Wednesday. The company has a market capitalization of $530.44 million, a PE ratio of -2.99 and a beta of 1.77. The company has a fifty day moving average of $5.21 and a 200 day moving average of $6.98. Valneva has a 1 year low of $4.75 and a 1 year high of $12.25. The company has a debt-to-equity ratio of 2.14, a current ratio of 2.14 and a quick ratio of 1.60.

Institutional Trading of Valneva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marex Group plc purchased a new position in Valneva in the second quarter valued at $64,000. XTX Topco Ltd purchased a new stake in shares of Valneva during the 4th quarter worth about $94,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of Valneva during the 3rd quarter worth about $124,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. The Goldman Sachs Group downgraded Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a research report on Wednesday, April 22nd. TD Cowen initiated coverage on Valneva in a report on Tuesday. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, Guggenheim set a $11.00 price target on Valneva in a research report on Thursday, April 16th. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $11.98.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.